Research programme: antibody therapeutics - Alder Biopharmaceuticals/Merck & Co

Drug Profile

Research programme: antibody therapeutics - Alder Biopharmaceuticals/Merck & Co

Latest Information Update: 13 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alder Biopharmaceuticals; Schering-Plough
  • Developer Alder Biopharmaceuticals; Merck & Co
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 25 Aug 2009 Preclinical development is ongoing in USA
  • 11 Jun 2009 Alder and Schering-Plough expand collaboration to identify and develop therapeutic monoclonal antibodies in the USA
  • 14 Dec 2005 Preclinical trials in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top